GASTROENTEROLOGY INFUSION REFERRAL FORM



PATIENT INFORMATION

Last Name	First Name			DOB	
Gender	Last 4 SSN			Primary Language	
Address					
City		State		ZIP	
Email					
Home Phone	Work Phone			Cell Phone	
Primary Contact Method (check one)	Cell Phone Home Phone Work Pho Text Email Primary Caregiver ON NOT CONTACT				
Primary Caregiver/Alt Contact Name (If applicable)					
Caregiver/Alt Contact Email			Caregi	ver/Alt Contact Phone	

PRESCRIBER INFORMATION

Name of Contact Send	ling Referral		Title
Preferred Contact Method (check one)	□ Email □ Phone □ Fax	Referral Conta	ct Email
Office Phone		Office Fax	
Practice / Facility Name	e		
Address			
City		State	ZIP
Prescriber Name / Spe	cialty		
Prescriber State Licens	e #		DEA #
NPI #			Medicaid UPIN #

INSURANCE INFORMATION

Insurance Provider		Plan ID #
BIN#:	PCN#:	RX Group#:
Insured's Name		Relationship to Patient

Eligible for Medicare (check one)	□ Yes □ No	If yes, list Medicare #	
Prescription Card (check one)	□ Yes □ No	lf yes, list carrier	

Please include a copy of the front and back of insurance card.

CLINICAL INFORMATION

Prescription Type	□ Naïve/New Start □ Therapy Restart □ Existing Treatment	Therapy Start Date		
Sample/Starter Product Provided? □Yes □No	lf yes, Provide Qty	Date Sample Provided		
Allergies NKDA Drug Allergies (please list)				
Therapies Tried and Failed (pl	ease list medications)			
Concurrent Medications				

Patient Height (cm/in)		Patient Weight (kg/lbs)		Date Obtained
Ship to Address		ne □Prescriber's Office er (please list)	2	
ICD-10 Codes	□ K51.	.90 Crohn's disease unspe .90 Ulcerative colitis, uns er	pecifie	d, without complications

tEV:031623

We accept Escribe and fax prescriptions.

PRESCRIPTIONS

Patient Last	Name
--------------	------

Patient First Name

DOB

Total RXs

REV.031623

PRESCRIPTION INFORMATION

MEDICATION	ROUTE	DOSE/STRENGTH	DIRECTIONS	QTY	REFILLS
□ Entyvio (vedolizumab)	□IV	Starting Dose □ Infuse 300 mg IV at weeks 0, 2, 6 and then every 8 weeks therafter Maintenance Dose □ Infuse 300 mg IV every 8 weeks	□ Reconstitute each vial of Entyvio with 4.8 mL of sterile water and dilute in 250 mL of NS or sterile Lactated Ringers. Infuse over 30 minutes	□ 1 month □ 3 months □	□ 1 year □
□ Remicade (infliximab) Biosimilars: □ Avsola □ Inflectra □ Infliximab □ Renflexis	١V	Starting Dose 100 mg vial Starting Dose 100 mg vial Smg/kg Pt weight(kg) =mg IV every 8 weeks Maintenance dose 100 mg vial Smg/kg Pt weight(kg) =mg IV every 8 weeks Other	□ Reconstitute each vial of Remicade with 10 mL of sterile water. Dilute desired does in NS 250 mL to be infused over a period NOT less than 2 hours. □ Additional directions (include daily, weekly, cyclic, one-time, duration of therapy, etc.) 	□ 1 month □ 3 months □	□ 1 year □
□ Stelara (ustekinumab	□IV	□ 130 mg/26 mL Vial (weight-based) Current Weight: kg	Induction Dose: Infuse: □ <55 kg: 260 mg IV as a single dose □ >55 kg to 85 kg: 390 mg IV as a single dose □ >85 kg: 520 mg IV as a single dose	2 Vials 3 Vials 4 Vials	0
Ustekinumab	□ SUBQ	□ 90 mg/1 mL PFS	Maintenance Dose: □ Inject 90 mg SubQ 8 weeks after first IV dose, then every 8 weeks thereafter	1	
□ Normal Saline □ D5W	□IV	□ 3 mL □ 5 mL □	□ Before and after infusion □	□ 1 month □ 3 months □	□ 1 year □
□ Heparin 10 units/mL □ Heparin 100 units/mL	□IV	□ 3 mL □ 5 mL □	□ After infusion □	□ 1 month □ 3 months □	□ 1 year □
Diphenhydramine	□ PO □ IV □ IM	□ 25 mg □ 50 mg □	After infusion PRN Allergic Reaction:	□With each infusion □	□ 1 year □
Acetaminophen	□PO	□ 325 mg □ 500 mg □ 650 mg □ 1 gm □	□ Pre-Med:	□With each infusion □	□ 1 year □
□ Epinephrine	□ IM □ SQ	□ Adult 1:1000, 0.3 mL (>30kg/>66lbs) □ Peds 1:2000, 0.3 mL (15-30kg/33-66lbs)	PRN Anaphylaxis Repeating Dose:	□ Once □	□ 1 year
□ Other:					
□ Vascular Access Method	□ periph	eral 🗆 central 🗆 other:	· 	·	

Lab Orders

Skilled nursing visits as needed to establish venous access administer medication and assess general status and response to therapy. Dispense 1 month of drug, flushes, needles, syringes, ancillary supplies and medical equipment necessary to establish access and administer medication. Prescription to include all necessary ancillary supplies (needle, syringes, etc). If shipped to physician's office, physician accepts on behalf of patient for administration in office.

Patient Support Programs: Please have patient sign and date to enroll in pharmaceutical company assisted support program.

Patient Signature

	/	 ./	
Date			

Account Manager

Prescriber Authorization (No stamps. Signature and date must be completed in prescriber's handwriting.)

Prescriber Signature

	_/	/	_
Dat	e		
	/	/	
Dat	е —		

Supervising Physician Signature (Dispense as Written)

**The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements.

Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.